Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04626674 · ClinicalTrials.gov registry record · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
A Phase 1 study of Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 5
- Study locations
NCT04626674: Recruiting Phase 1 study of Muscular Dystrophy, Duchenne, sponsored by Sarepta Therapeutics.
NCT04626674 is a Phase 1 study of Muscular Dystrophy, Duchenne that is actively recruiting participants, run by Sarepta Therapeutics. The registered enrollment target is 83 participants, roughly in line with the 87-participant average among 4 other Muscular Dystrophy, Duchenne trials with a reported enrollment target. The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04626674, a Phase 1 study of Muscular Dystrophy, Duchenne, is actively recruiting participants, sponsored by Sarepta Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with DMD. The maximum participant duration for this study is 156 weeks.
Conditions Studied
Interventions
- GENETIC delandistrogene moxeparvovec
Study Locations (5)
California
- Stanford University - Palo Alto
- University of California, Davis - Sacramento
Missouri
- Washington University in St. Louis - St Louis
Ohio
- Nationwide Children's Hospital - Columbus
Virginia
- Children's Hospital of The King's Daughters - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2020-11-23 |
| Est. Completion | 2028-02-29 |
| Phase | Phase 1 |
What NCT04626674 shows while recruiting
NCT04626674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, roughly in line with the 87-participant average among 4 other Muscular Dystrophy, Duchenne trials with a reported enrollment target.
The record links to 1 condition, with Muscular Dystrophy, Duchenne appearing as the primary indexed condition, and to 1 intervention - of which delandistrogene moxeparvovec is the first listed.
NCT04626674 lists 5 locations in 4 states (California, Missouri, Ohio).
Frequently Asked Questions
What is clinical trial NCT04626674 about?
NCT04626674 is a clinical study titled "A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)". This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with DMD. The maximum participant duration for this study is 156 weeks.
What is the current status of trial NCT04626674?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2020-11-23. Estimated completion is 2028-02-29.
What conditions does trial NCT04626674 study?
This clinical trial studies the following conditions: Muscular Dystrophy, Duchenne.
What interventions are being tested in trial NCT04626674?
The interventions under investigation include: delandistrogene moxeparvovec (GENETIC).
Who is sponsoring clinical trial NCT04626674?
This trial is sponsored by Sarepta Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04626674 being conducted?
This trial has 5 study locations across California, Missouri, Ohio, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscular Dystrophy, Duchenne
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 (Vesleteplirsen) in Patients With Duchenne Muscular Dystrophy (DMD)
COMPLETED · Phase 1
-
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
ACTIVE NOT RECRUITING · Phase 3
-
Phase III Study of Idebenone in Duchenne Muscular Dystrophy (DMD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
- NCT05419089 · 83 participants · Phase 2
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI